Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis

2011 ◽  
Vol 51 (9) ◽  
pp. 1310-1318 ◽  
Author(s):  
Muhammad Baluom ◽  
Emil Samara ◽  
Elliott B. Grossbard ◽  
David T.-W. Lau
Keyword(s):  
Rheumatoid Arthritis ◽  
Kinase Inhibitor ◽  
Syk Kinase

scholarly journals Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

2008 ◽  
Vol 58 (11) ◽  
pp. 3309-3318 ◽  
Author(s):  
Michael E. Weinblatt ◽  
Arthur Kavanaugh ◽  
Ruben Burgos-Vargas ◽  
Ara H. Dikranian ◽  
Gabriel Medrano-Ramirez ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Kinase Inhibitor ◽  
Controlled Trial ◽  
Syk Kinase

scholarly journals Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
Han Ni ◽  
Soe Moe ◽  
Kay Thi Myint ◽  
Aung Htet
Keyword(s):  
Rheumatoid Arthritis ◽  
Safety Profile ◽  
Kinase Inhibitor ◽  
Meta Analysis ◽  
Janus Kinase ◽  
Serious Adverse Events ◽  
Janus Kinase Inhibitor ◽  
Immune Modulators ◽  
Serious Infections

Since the introduction of immune modulators in the treatment of rheumatoid arthritis (RA), there has been hope that orally effective biologic agents would be developed. Tofacitinib, a Janus kinase inhibitor, has become the first oral biologic to receive approval for use in active RA patients. This paper reviews the efficacy and safety profile of Tofacitinib at dosages of 5 mg and 10 mg twice daily. Remarkable improvement in terms of ACR 20 response and HAQ-DI score was noted at month 3 and month 6. DAS 28-4 ESR < 2.6 achievement was noticeably obvious at month 6 for both dosages. No significant serious adverse events, serious infections, neutropenia, or anaemia were observed compared to placebo. In fact, Tofacitinib 5 mg was even found to have significant protective effect of anaemia in the meta-analysis (P=0.004). Tofacitinib has a noticeable efficacy in controlling disease activity in RA with a manageable safety profile. However, longer studies are needed for its long-term safety profile.

scholarly journals Extensive Tinea Associated with Tofacitinib Therapy Masquerading as New-Onset SCLE

2020 ◽  
Vol 4 (5) ◽  
pp. 456-459
Author(s):  
Connor R Buechler ◽  
Elena Kurland ◽  
Jesse Veenstra
Keyword(s):  
Rheumatoid Arthritis ◽  
Tinea Capitis ◽  
Kinase Inhibitor ◽  
Autoimmune Disorder ◽  
Connective Tissue Disorder ◽  
Janus Kinase ◽  
Immunomodulatory Agents ◽  
Janus Kinase Inhibitor ◽  
Infection Monitoring ◽  
New Onset

Rheumatoid arthritis is a chronic autoimmune disorder that often requires treatment with immunomodulatory agents, however, such interventions are not without risk of opportunistic infection.  Monitoring for such conditions is critical, whereas recognition and treatment can prove challenging at times, as they may manifest with an atypical presentation or masquerade as another condition entirely. We present here a case of extensive tinea corporis with concomitant tinea capitis masquerading as new-onset connective tissue disorder in a patient being treated for rheumatoid arthritis with the Janus kinase inhibitor tofacitinib.

Sign in / Sign up

Export Citation Format

Share Document